Further research is needed to compare the effectiveness of SGM-101 with ICG and assess its potential benefits in patients with primary tumours, lymph node metastases, or peritoneal metastases expressing carcinoembryonic antigen (CEA). The gene discussed is CEACAM5; the disease is neoplasm.